Re: Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84 (multiple letters)

European Urology

Volumn 47, Issue 3, 2005, Pages 422-

  Weston, Philip ^a   Persson, Bo Eric ^b,c   Weckermann, Dorothea ^d  

^a PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

^b Elisabethsjukhuset   (Sweden)

^c Ferring Pharmaceuticals AS   (Denmark)

^d NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEGARELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; UNCLASSIFIED DRUG;

CANCER HORMONE THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 13844281492     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.11.015     Document Type: Letter

References (2)

1. P.M.T. Weston J. Hammonds K. Vaughton T.K. Olesen J.K. Jensen O. Eskerod Degarelix; a novel GnRH antagonist tested in a multicenter randomised dose-finding study in prostate cancer patients BJU Int 94 Suppl 2 2004 57
2. Ferring Pharmaceuticals A/S. Unpublished data.